Gene and cytokine expression profiles of metastatic colorectal cancer patients post reovirus administration.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
reovirus
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] Reovirus demonstrates potential as an immunomodulatory and cytotoxic adjuvant in -mutant mCRC by altering key signaling pathways and cytokine profiles. These findings support further investigation into its potential therapeutic contributions.
[BACKGROUND] Colorectal cancer (CRC), encompassing both colon and rectal carcinogenesis, is a major health concern.
APA
Zweig V, Goel S, Maitra R (2026). Gene and cytokine expression profiles of metastatic colorectal cancer patients post reovirus administration.. World journal of clinical oncology, 17(2), 113428. https://doi.org/10.5306/wjco.v17.i2.113428
MLA
Zweig V, et al.. "Gene and cytokine expression profiles of metastatic colorectal cancer patients post reovirus administration.." World journal of clinical oncology, vol. 17, no. 2, 2026, pp. 113428.
PMID
41810348
Abstract
[BACKGROUND] Colorectal cancer (CRC), encompassing both colon and rectal carcinogenesis, is a major health concern. Metastatic CRC (mCRC) is the third most common cancer and the second leading cause of cancer-related death in United States adults. Despite advances in therapy, the 5-year survival rate remains low at 15%. mutations contribute to treatment resistance by altering the tumor microenvironment, necessitating novel therapeutic approaches.
[AIM] To evaluate immunomodulatory and cytotoxic potential of reovirus as an adjuvant therapy in -mutant-mCRC patients by analyzing gene and cytokine expression.
[METHODS] Five -mutant mCRC patients were treated with reovirus. Serum samples were collected at five time points over 15 days. Cytokine levels were measured using enzyme-linked immunosorbent assay, and transcriptomic profiling was performed to assess gene expression. Data were analyzed using the 2 method, and statistical significance was determined two-tailed -tests ( < 0.05).
[RESULTS] Out of 271 genes associated with Janus kinase/signal transducer and activator of transcription, Ras, Wnt, and phosphoinositide 3-kinase- alpha serine/threonine-protein kinase pathways, 85 showed significant modulation. Additionally, 17 of 25 cytokines were significantly altered. Reovirus induced changes in both gene and cytokine expression, suggesting activation of a complex intracellular signaling network.
[CONCLUSION] Reovirus demonstrates potential as an immunomodulatory and cytotoxic adjuvant in -mutant mCRC by altering key signaling pathways and cytokine profiles. These findings support further investigation into its potential therapeutic contributions.
[AIM] To evaluate immunomodulatory and cytotoxic potential of reovirus as an adjuvant therapy in -mutant-mCRC patients by analyzing gene and cytokine expression.
[METHODS] Five -mutant mCRC patients were treated with reovirus. Serum samples were collected at five time points over 15 days. Cytokine levels were measured using enzyme-linked immunosorbent assay, and transcriptomic profiling was performed to assess gene expression. Data were analyzed using the 2 method, and statistical significance was determined two-tailed -tests ( < 0.05).
[RESULTS] Out of 271 genes associated with Janus kinase/signal transducer and activator of transcription, Ras, Wnt, and phosphoinositide 3-kinase- alpha serine/threonine-protein kinase pathways, 85 showed significant modulation. Additionally, 17 of 25 cytokines were significantly altered. Reovirus induced changes in both gene and cytokine expression, suggesting activation of a complex intracellular signaling network.
[CONCLUSION] Reovirus demonstrates potential as an immunomodulatory and cytotoxic adjuvant in -mutant mCRC by altering key signaling pathways and cytokine profiles. These findings support further investigation into its potential therapeutic contributions.